Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia

Karen K. Ballen, Ann E. Woolfrey, Xiaochun Zhu, Kwang Woo Ahn, Baldeep Wirk, Mukta Arora, Biju George, Bipin N. Savani, Brian Bolwell, David L. Porter, Ed Copelan, Gregory Hale, Harry C. Schouten, Ian Lewis, Jean Yves Cahn, Joerg Halter, Jorge Cortes, Matt E. Kalaycio, Joseph Antin, Mahmoud D. AljurfMatthew H. Carabasi, Mehdi Hamadani, Philip McCarthy, Steven Pavletic, Vikas Gupta, H. Joachim Deeg, Richard T. Maziarz, Mary M. Horowitz, Wael Saber

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Allogeneic hematopoietic cell transplantation (HCT) is curative for selected patients with advanced essential thrombocythemia (ET) or polycythemia vera (PV). From 1990 to 2007, 75 patients with ET (median age 49 years) and 42 patients with PV (median age 53 years) underwent transplantations at the Fred Hutchinson Cancer Research Center (FHCRC; n = 43) or at other Center for International Blood and Marrow Transplant Research (CIBMTR) centers (n = 74). Thirty-eight percent of the patients had splenomegaly and 28% had a prior splenectomy. Most patients (69% for ET and 67% for PV) received a myeloablative (MA) conditioning regimen. Cumulative incidence of neutrophil engraftment at 28 days was 88% for ET patients and 90% for PV patients. Acute graft-versus-host disease (aGVHD) grades II to IV occurred in 57% and 50% of ET and PV patients, respectively. The 1-year treatment-related mortality (TRM) was 27% for ET and 22% for PV. The 5-year cumulative incidence of relapse was 13% for ET and 30% for PV. Five-year survival/progression-free survival (PFS) was 55%/47% and 71%/48% for ET and PV, respectively. Patients without splenomegaly had faster neutrophil and platelet engraftment, but there were no differences in TRM, survival, or PFS. Presence of myelofibrosis (MF) did not affect engraftment or TRM. Over 45% of the patients who undergo transplantations for ET and PV experience long-term PFS.

Original languageEnglish (US)
Pages (from-to)1446-1454
Number of pages9
JournalBiology of Blood and Marrow Transplantation
Volume18
Issue number9
DOIs
StatePublished - Sep 1 2012

Fingerprint

Essential Thrombocythemia
Polycythemia Vera
Cell Transplantation
Disease-Free Survival
Splenomegaly
Mortality
Neutrophils
Transplantation
Primary Myelofibrosis
Survival
Incidence
Graft vs Host Disease
Splenectomy
Research
Therapeutics
Blood Platelets
Bone Marrow
Transplants

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Ballen, Karen K. ; Woolfrey, Ann E. ; Zhu, Xiaochun ; Ahn, Kwang Woo ; Wirk, Baldeep ; Arora, Mukta ; George, Biju ; Savani, Bipin N. ; Bolwell, Brian ; Porter, David L. ; Copelan, Ed ; Hale, Gregory ; Schouten, Harry C. ; Lewis, Ian ; Cahn, Jean Yves ; Halter, Joerg ; Cortes, Jorge ; Kalaycio, Matt E. ; Antin, Joseph ; Aljurf, Mahmoud D. ; Carabasi, Matthew H. ; Hamadani, Mehdi ; McCarthy, Philip ; Pavletic, Steven ; Gupta, Vikas ; Deeg, H. Joachim ; Maziarz, Richard T. ; Horowitz, Mary M. ; Saber, Wael. / Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia. In: Biology of Blood and Marrow Transplantation. 2012 ; Vol. 18, No. 9. pp. 1446-1454.
@article{d63480c372654596ab546448e5fa619c,
title = "Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia",
abstract = "Allogeneic hematopoietic cell transplantation (HCT) is curative for selected patients with advanced essential thrombocythemia (ET) or polycythemia vera (PV). From 1990 to 2007, 75 patients with ET (median age 49 years) and 42 patients with PV (median age 53 years) underwent transplantations at the Fred Hutchinson Cancer Research Center (FHCRC; n = 43) or at other Center for International Blood and Marrow Transplant Research (CIBMTR) centers (n = 74). Thirty-eight percent of the patients had splenomegaly and 28{\%} had a prior splenectomy. Most patients (69{\%} for ET and 67{\%} for PV) received a myeloablative (MA) conditioning regimen. Cumulative incidence of neutrophil engraftment at 28 days was 88{\%} for ET patients and 90{\%} for PV patients. Acute graft-versus-host disease (aGVHD) grades II to IV occurred in 57{\%} and 50{\%} of ET and PV patients, respectively. The 1-year treatment-related mortality (TRM) was 27{\%} for ET and 22{\%} for PV. The 5-year cumulative incidence of relapse was 13{\%} for ET and 30{\%} for PV. Five-year survival/progression-free survival (PFS) was 55{\%}/47{\%} and 71{\%}/48{\%} for ET and PV, respectively. Patients without splenomegaly had faster neutrophil and platelet engraftment, but there were no differences in TRM, survival, or PFS. Presence of myelofibrosis (MF) did not affect engraftment or TRM. Over 45{\%} of the patients who undergo transplantations for ET and PV experience long-term PFS.",
author = "Ballen, {Karen K.} and Woolfrey, {Ann E.} and Xiaochun Zhu and Ahn, {Kwang Woo} and Baldeep Wirk and Mukta Arora and Biju George and Savani, {Bipin N.} and Brian Bolwell and Porter, {David L.} and Ed Copelan and Gregory Hale and Schouten, {Harry C.} and Ian Lewis and Cahn, {Jean Yves} and Joerg Halter and Jorge Cortes and Kalaycio, {Matt E.} and Joseph Antin and Aljurf, {Mahmoud D.} and Carabasi, {Matthew H.} and Mehdi Hamadani and Philip McCarthy and Steven Pavletic and Vikas Gupta and Deeg, {H. Joachim} and Maziarz, {Richard T.} and Horowitz, {Mary M.} and Wael Saber",
year = "2012",
month = "9",
day = "1",
doi = "10.1016/j.bbmt.2012.03.009",
language = "English (US)",
volume = "18",
pages = "1446--1454",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "9",

}

Ballen, KK, Woolfrey, AE, Zhu, X, Ahn, KW, Wirk, B, Arora, M, George, B, Savani, BN, Bolwell, B, Porter, DL, Copelan, E, Hale, G, Schouten, HC, Lewis, I, Cahn, JY, Halter, J, Cortes, J, Kalaycio, ME, Antin, J, Aljurf, MD, Carabasi, MH, Hamadani, M, McCarthy, P, Pavletic, S, Gupta, V, Deeg, HJ, Maziarz, RT, Horowitz, MM & Saber, W 2012, 'Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia', Biology of Blood and Marrow Transplantation, vol. 18, no. 9, pp. 1446-1454. https://doi.org/10.1016/j.bbmt.2012.03.009

Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia. / Ballen, Karen K.; Woolfrey, Ann E.; Zhu, Xiaochun; Ahn, Kwang Woo; Wirk, Baldeep; Arora, Mukta; George, Biju; Savani, Bipin N.; Bolwell, Brian; Porter, David L.; Copelan, Ed; Hale, Gregory; Schouten, Harry C.; Lewis, Ian; Cahn, Jean Yves; Halter, Joerg; Cortes, Jorge; Kalaycio, Matt E.; Antin, Joseph; Aljurf, Mahmoud D.; Carabasi, Matthew H.; Hamadani, Mehdi; McCarthy, Philip; Pavletic, Steven; Gupta, Vikas; Deeg, H. Joachim; Maziarz, Richard T.; Horowitz, Mary M.; Saber, Wael.

In: Biology of Blood and Marrow Transplantation, Vol. 18, No. 9, 01.09.2012, p. 1446-1454.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia

AU - Ballen, Karen K.

AU - Woolfrey, Ann E.

AU - Zhu, Xiaochun

AU - Ahn, Kwang Woo

AU - Wirk, Baldeep

AU - Arora, Mukta

AU - George, Biju

AU - Savani, Bipin N.

AU - Bolwell, Brian

AU - Porter, David L.

AU - Copelan, Ed

AU - Hale, Gregory

AU - Schouten, Harry C.

AU - Lewis, Ian

AU - Cahn, Jean Yves

AU - Halter, Joerg

AU - Cortes, Jorge

AU - Kalaycio, Matt E.

AU - Antin, Joseph

AU - Aljurf, Mahmoud D.

AU - Carabasi, Matthew H.

AU - Hamadani, Mehdi

AU - McCarthy, Philip

AU - Pavletic, Steven

AU - Gupta, Vikas

AU - Deeg, H. Joachim

AU - Maziarz, Richard T.

AU - Horowitz, Mary M.

AU - Saber, Wael

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Allogeneic hematopoietic cell transplantation (HCT) is curative for selected patients with advanced essential thrombocythemia (ET) or polycythemia vera (PV). From 1990 to 2007, 75 patients with ET (median age 49 years) and 42 patients with PV (median age 53 years) underwent transplantations at the Fred Hutchinson Cancer Research Center (FHCRC; n = 43) or at other Center for International Blood and Marrow Transplant Research (CIBMTR) centers (n = 74). Thirty-eight percent of the patients had splenomegaly and 28% had a prior splenectomy. Most patients (69% for ET and 67% for PV) received a myeloablative (MA) conditioning regimen. Cumulative incidence of neutrophil engraftment at 28 days was 88% for ET patients and 90% for PV patients. Acute graft-versus-host disease (aGVHD) grades II to IV occurred in 57% and 50% of ET and PV patients, respectively. The 1-year treatment-related mortality (TRM) was 27% for ET and 22% for PV. The 5-year cumulative incidence of relapse was 13% for ET and 30% for PV. Five-year survival/progression-free survival (PFS) was 55%/47% and 71%/48% for ET and PV, respectively. Patients without splenomegaly had faster neutrophil and platelet engraftment, but there were no differences in TRM, survival, or PFS. Presence of myelofibrosis (MF) did not affect engraftment or TRM. Over 45% of the patients who undergo transplantations for ET and PV experience long-term PFS.

AB - Allogeneic hematopoietic cell transplantation (HCT) is curative for selected patients with advanced essential thrombocythemia (ET) or polycythemia vera (PV). From 1990 to 2007, 75 patients with ET (median age 49 years) and 42 patients with PV (median age 53 years) underwent transplantations at the Fred Hutchinson Cancer Research Center (FHCRC; n = 43) or at other Center for International Blood and Marrow Transplant Research (CIBMTR) centers (n = 74). Thirty-eight percent of the patients had splenomegaly and 28% had a prior splenectomy. Most patients (69% for ET and 67% for PV) received a myeloablative (MA) conditioning regimen. Cumulative incidence of neutrophil engraftment at 28 days was 88% for ET patients and 90% for PV patients. Acute graft-versus-host disease (aGVHD) grades II to IV occurred in 57% and 50% of ET and PV patients, respectively. The 1-year treatment-related mortality (TRM) was 27% for ET and 22% for PV. The 5-year cumulative incidence of relapse was 13% for ET and 30% for PV. Five-year survival/progression-free survival (PFS) was 55%/47% and 71%/48% for ET and PV, respectively. Patients without splenomegaly had faster neutrophil and platelet engraftment, but there were no differences in TRM, survival, or PFS. Presence of myelofibrosis (MF) did not affect engraftment or TRM. Over 45% of the patients who undergo transplantations for ET and PV experience long-term PFS.

UR - http://www.scopus.com/inward/record.url?scp=84865198731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865198731&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2012.03.009

DO - 10.1016/j.bbmt.2012.03.009

M3 - Article

C2 - 22449610

AN - SCOPUS:84865198731

VL - 18

SP - 1446

EP - 1454

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 9

ER -